Eli Lilly and Company (NYSE: LLY) is a healthcare company, listed on the NYSE. Alpha Stocks Insight tracks LLY across all major catalysts: quarterly earnings reports, analyst upgrades and downgrades, mergers and acquisitions, regulatory decisions, and significant price moves driven by sector or macro developments. This page centralises 13 articles published since May 1, 2026, providing investors with timely, data-driven analysis of Eli Lilly and Company's financial performance and competitive position. New coverage is added each trading day.
Price
$1,196.03
Today
+0.86%
Mkt Cap
$1126.4B
P/E
44.6x
52W High
$1,249.45
52W Low
$623.78
Data via Finnhub · refreshes hourly · not financial advice
Lilly plans to pull 340B discounted drug pricing from hospitals that missed claims data reporting deadlines, a compliance push with real revenue implications.
FDA clears an every-eight-weeks maintenance dose for Lilly's Ebglyss, adding dosing flexibility to a drug already holding broad national pharmacy benefit manager coverage.
Eli Lilly's obesity and diabetes candidate retatrutide showed significant weight loss and improved sleep apnea in Phase 3 data presented at ADA — what the results mean for LLY's GLP-1 pipeline.
Eli Lilly secured full obesity portfolio coverage from all three major U.S. PBMs and added Sesame and WW Med+ to LillyDirect — here's what it means for LLY.
CVS Health's new tie-up with LillyDirect adds WeightWatchers' Med+ program to Lilly's platform — here's what it means for LLY's weight-loss market position.
Eli Lilly's non-metabolic portfolio grew 160% as management argues LLY is a multi-franchise pharma leader — here's what investors need to know.
$1.9B partnership with Ascidian brings gene-editing tech into Eli Lilly's pipeline. The deal signals pharma's growing bet on genetic therapies—here's what it means for LLY.
CVS Caremark adds LLY's Zepbound and Foundayo to formulary, expanding access to millions of Americans—what it means for obesity drug sales.
Analysts revised LLY's fair value estimate to $1,211.03/share amid retatrutide Phase 3 data — here's what the evolving GLP-1 narrative means for investors.
Eli Lilly is spending $3.8B to acquire three vaccine developers — LimmaTech, Curevo, and a third — in a major pipeline expansion. What it means for LLY's growth outlook.
Eli Lilly announces Phase III trial results for oral GLP-1 treatment Foundayo, showing significant weight-loss benefits in elderly populations, expanding the company's weight-loss drug pipeline.
Eli Lilly acquires Engage Biologics for up to $202 million and reports Phase 3 obesity drug data showing 'meaningful' weight loss. Stock rose 1.31%.
Shares jump 3% as stable pricing supports results while oral obesity medication gains early traction with physicians.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.